全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 926037-48-1 |
|---|---|---|---|
| 分子式 | C27H21F3N8O | 纯度 | 98% |
| 分子量 | 530.5 | 货号 | abs47027997 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | a drug for the treatment of different ty | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Radotinib 926037-48-1
| 产品描述 | |
| 描述 | Radotinib, and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)[1] with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors |
| 纯度 | 98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 拉多替尼; IY-5511 |
| 外观 | Off white to light yellow powder |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶点 | BCR-ABL1 |
| In vitro(体外研究) | In vitro, Radotinib binds BCR-ABL1 and reduces phosphorylation of CrkL, a BCR-ABL1 target protein. Radotinib also effectively inhibits the proliferation of common mutant clones of BCR-ABL1, with the exception of T315I. In AML cells, radotinib significantly decreases the cell viability, promotes differentiation, and induces CD11b expression and apoptosis. In NB4, THP-1, and Kasumi-1 cells, radotinib also induces CD11b expression, and decreases the viability. |
| 参考文献 | |
| 参考文献 |
| 研究领域 | |
| 研究领域 | CancerOncoproteins/suppressorsOncoproteinsOther EpigeneticsTranscriptionCancer susceptibilityProto-oncogenes Signal TransductionProtein PhosphorylationTyrosine KinasesOther Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：